Table of Contents
Trial overview
ZIRCONIUM (89ZR) GIRENTUXIMAB is being studied in two authorised interventional trials.[1][2] Both trials focus on imaging, meaning they are designed to see how well scans can find tumors in specific patient groups.[1][2]
Who is being studied
One trial includes patients with suspected primary, recurrent, or metastatic clear cell renal cell carcinoma (ccRCC), which is a type of kidney cancer.[1] The other trial includes people with Von-Hippel Lindau (VHL) disease, a rare inherited condition linked to tumor growth.[2]
The first study is listed for metastatic renal cell carcinoma, meaning kidney cancer that has spread to other parts of the body.[1] The second study explores the role of Carbonic Anhydrase IX, also called CAIX, as a diagnostic and theranostic target in VHL disease.[2]
What the trials measure
The Phase 3 study compares the tumor detection rate of 68Ga-gozetotide PET-CT with ZIRCONIUM (89ZR) GIRENTUXIMAB PET-CT, both added to conventional contrast enhanced CT.[1] Its main outcome is tumor detectability, which means how well each scan can find tumors.[1]
The Phase 2 study measures the efficacy of CAIX-PET for detecting tumors in patients with VHL disease.[2] In simple terms, it asks whether the scan works well for finding tumors in this group.[2]
Trial phases and status
One study is Phase 3 and has an enrollment of 20 participants.[1] The other is Phase 2 and has an enrollment of 38 participants.[2]
Both studies are currently listed as Authorised.[1][2] They are both interventional studies, meaning researchers actively apply the imaging procedure and then measure the results.[1][2]
Trial details
The study titled ISEE-RCC study compares ZIRCONIUM (89ZR) GIRENTUXIMAB PET-CT with 68Ga-gozetotide PET-CT and conventional contrast enhanced CT in patients with suspected metastatic ccRCC.[1] Its brief summary says the study is exploratory and looks at tumor detection visually and semi-quantitatively, which means the scans are reviewed by eye and also by numbers.[1]
The study titled CAT-VHL – Exploring the role of Carbonic Anhydrase IX as diagnostic and Theranostic target in Von-Hippel Lindau disease evaluates CAIX-PET for detecting tumors in VHL disease.[2] Its brief summary says it is exploring Carbonic Anhydrase IX as a diagnostic and theranostic target, meaning a target that may help both with finding disease and guiding future care.[2]
